ArticleTransboundary and emerging diseases2026
Foot-and-Mouth Disease Virus Persistence Divergence Within Serotypes and Vaccine Doses in Vaccinated Cattle.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Foot-and-Mouth Disease Virus Persistence Divergence Within Serotypes and Vaccine Doses in Vaccinated Cattle.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Foot-and-mouth disease virus (FMDV) persistence in ruminants constitutes the potential risk of disease transmission. While vaccination effectively protects animals against clinical disease, more than 50% of vaccinated cattle can still develop persistent infection. Investigating the potential factors that influence the establishment of FMDV persistence in vaccinated cattle is critical for improving control and eradication strategies in epidemic regions. Here, cattle vaccinated with different doses of serotype O and serotype A vaccines were experimentally challenged with the homologous virus. The overall incidence of the carrier state was 22.5%. Although higher levels and prolonged detection of viral RNA in oesophagal-pharyngeal fluids (OPFs) were observed in the two higher-dose groups of both serotypes, neither viral serotype nor vaccine dose significantly influenced the final carrier incidence. Notably, most carriers showed a slower rise in antigen-specific and neutralizing antibody (NAb) titers postchallenge, resulting in significantly lower antibody titers during the early infection stage, irrespective of the viral serotypes or vaccine doses. Viral genomes and particles were predominantly localized within nasopharyngeal tissues, including the nasopharynx, soft palate, and adjacent lymph nodes and tonsils. In addition, carriers exhibited an increased number of germinal centers in the lymph nodes and tonsils. These findings provide novel insights into the immunological features associated with FMDV persistence in vaccinated cattle and offer a theoretical foundation for optimizing vaccine design and developing targeted immune intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.